Hiromichi Matsuoka1, Kazuhiro Yoshiuchi2, Atsuko Koyama1, Masatomo Otsuka3, Kazuhiko Nakagawa4. 1. Department of Medical Oncology,Division of Psychosomatic Medicine,Kinki University Faculty of Medicine,Osaka,Japan. 2. Department of Stress Sciences and Psychosomatic Medicine,Graduate School of Medicine,The University of Tokyo,Tokyo,Japan. 3. Department of Palliative Care Medicine,Sakai Hospital,Kinki University Faculty of Medicine,Osaka,Japan. 4. Department of Medical Oncology,Kinki University Faculty of Medicine,Osaka,Japan.
Abstract
OBJECTIVE: Delirium is a frequently encountered psychiatric disease in terminal cancer patients. However, the mechanism of delirium is unclear. The aim of our study was to investigate the relationship between administration of chemotherapy drugs that penetrate the blood-brain barrier (BBB) and the development of delirium in cancer patients. METHOD: We retrospectively analyzed 166 cancer patients (97 males, 69 females) continuously who died between September of 2007 and January of 2010 using a review of medical charts. Multiple logistic regression analysis was employed to investigate the effects of antineoplastic drugs penetrating the BBB on development of delirium in cancer patients with control for other risk factors. RESULTS: In multivariate analysis, antineoplastic drugs that penetrated the BBB were significantly associated with development of delirium (OR = 18.92, CI 95 = 1.08-333.04, p < 0.001). SIGNIFICANCE OF RESULTS: The use of chemotherapy drugs that penetrate the BBB may be a risk factor for delirium. This information may allow palliative care doctors and medical oncologists to predict which patients are at increased risk for delirium.
OBJECTIVE:Delirium is a frequently encountered psychiatric disease in terminal cancerpatients. However, the mechanism of delirium is unclear. The aim of our study was to investigate the relationship between administration of chemotherapy drugs that penetrate the blood-brain barrier (BBB) and the development of delirium in cancerpatients. METHOD: We retrospectively analyzed 166 cancerpatients (97 males, 69 females) continuously who died between September of 2007 and January of 2010 using a review of medical charts. Multiple logistic regression analysis was employed to investigate the effects of antineoplastic drugs penetrating the BBB on development of delirium in cancerpatients with control for other risk factors. RESULTS: In multivariate analysis, antineoplastic drugs that penetrated the BBB were significantly associated with development of delirium (OR = 18.92, CI 95 = 1.08-333.04, p < 0.001). SIGNIFICANCE OF RESULTS: The use of chemotherapy drugs that penetrate the BBB may be a risk factor for delirium. This information may allow palliative care doctors and medical oncologists to predict which patients are at increased risk for delirium.
Entities:
Keywords:
Blood–brain barrier; Cancer patients; Chemotherapeutic drugs; Delirium; P glycoprotein